N30 Pharmaceuticals, LLC
Records under this name other than patents N30 Pharmaceuticals, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to N30 Pharmaceuticals, LLC
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,921,562 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 8,673,961 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents Formerly held Lapsed on the fee record Ended Mar 18, 2026 · USPTO record | Lapsed on the fee record | Ended Mar 18, 2026 | USPTO record |
| US 9,856,219 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors Formerly held Lapsed on the fee record Ended Jan 2, 2026 · USPTO record | Lapsed on the fee record | Ended Jan 2, 2026 | USPTO record |
| US 9,814,700 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents Formerly held Lapsed on the fee record Ended Nov 14, 2025 · USPTO record | Lapsed on the fee record | Ended Nov 14, 2025 | USPTO record |
| US 9,498,466 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents Formerly held Lapsed on the fee record Ended Nov 22, 2024 · USPTO record | Lapsed on the fee record | Ended Nov 22, 2024 | USPTO record |
| US 9,433,618 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors Formerly held Lapsed on the fee record Ended Sep 6, 2024 · USPTO record | Lapsed on the fee record | Ended Sep 6, 2024 | USPTO record |
| US 9,315,462 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors Formerly held Lapsed on the fee record Ended Apr 19, 2024 · USPTO record | Lapsed on the fee record | Ended Apr 19, 2024 | USPTO record |
| US 9,180,119 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents Formerly held Lapsed on the fee record Ended Nov 10, 2023 · USPTO record | Lapsed on the fee record | Ended Nov 10, 2023 | USPTO record |
| US 9,139,528 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors Formerly held Lapsed on the fee record Ended Sep 22, 2023 · USPTO record | Lapsed on the fee record | Ended Sep 22, 2023 | USPTO record |
| US 8,957,105 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents Formerly held Lapsed on the fee record Ended Feb 17, 2023 · USPTO record | Lapsed on the fee record | Ended Feb 17, 2023 | USPTO record |